Literature DB >> 19375390

Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome.

Laurence E Cheng1, Bittoo Kanwar, Haig Tcheurekdjian, James P Grenert, Mica Muskat, Melvin B Heyman, Joseph M McCune, Diane W Wara.   

Abstract

The NEMO syndrome is a primary immunodeficiency with immune and non-immune manifestations. The immune deficiency is heterogeneous showing defects in humoral, innate, and cell-mediated immunity. While the clinical aspects of the immunodeficiency are increasingly well understood, little is known about autoimmune manifestations in NEMO patients. We therefore sought to examine serologic markers of systemic inflammation and intestinal pathology in a kindred of patients with the NEMO syndrome. We observed persistent elevation of erythrocyte sedimentation rates in five patients, and two were symptomatic, with a chronic but atypical enterocolitis. Though pathologic lesions in these two patients were consistent with acute inflammation, sustained clinical improvement was only achieved with systemic and/or topical glucocorticoid therapy. Our data suggest that some patients with the NEMO syndrome exhibit persistent elevation of inflammatory markers similar to systemic autoimmune diseases and may subsequently develop an atypical enterocolitis.

Entities:  

Mesh:

Year:  2009        PMID: 19375390      PMCID: PMC2800791          DOI: 10.1016/j.clim.2009.03.514

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  33 in total

1.  Serum C-reactive protein in the differential diagnosis of childhood meningitis.

Authors:  R Tatara; H Imai
Journal:  Pediatr Int       Date:  2000-10       Impact factor: 1.524

Review 2.  Autoimmunity in human primary immunodeficiency diseases.

Authors:  Peter D Arkwright; Mario Abinun; Andrew J Cant
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

3.  Mature T cells depend on signaling through the IKK complex.

Authors:  Marc Schmidt-Supprian; Gilles Courtois; Jane Tian; Anthony J Coyle; Alain Israël; Klaus Rajewsky; Manolis Pasparakis
Journal:  Immunity       Date:  2003-09       Impact factor: 31.745

4.  Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation.

Authors:  Marc Schmidt-Supprian; Jane Tian; Ethan P Grant; Manolis Pasparakis; René Maehr; Huib Ovaa; Hidde L Ploegh; Anthony J Coyle; Klaus Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-16       Impact factor: 11.205

Review 5.  Inherited disorders of NF-kappaB-mediated immunity in man.

Authors:  Anne Puel; Capucine Picard; Cheng-Lung Ku; Asma Smahi; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2004-02       Impact factor: 7.486

6.  Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity.

Authors:  Eric P Hanson; Linda Monaco-Shawver; Laura A Solt; Lisa A Madge; Pinaki P Banerjee; Michael J May; Jordan S Orange
Journal:  J Allergy Clin Immunol       Date:  2008-10-11       Impact factor: 10.793

7.  The zinc finger mutation C417R of I-kappa B kinase gamma impairs lipopolysaccharide- and TNF-mediated NF-kappa B activation through inhibiting phosphorylation of the I-kappa B kinase beta activation loop.

Authors:  Fan Yang; Junro Yamashita; Eric Tang; Hom-Lay Wang; Kunliang Guan; Cun-Yu Wang
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

Review 8.  NF-kappaB regulation in the immune system.

Authors:  Qiutang Li; Inder M Verma
Journal:  Nat Rev Immunol       Date:  2002-10       Impact factor: 53.106

9.  The carboxyl-terminal region of IkappaB kinase gamma (IKKgamma) is required for full IKK activation.

Authors:  Constantin Makris; Jaclyn L Roberts; Michael Karin
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

10.  Differential requirement for Rel/nuclear factor kappa B family members in natural killer T cell development.

Authors:  Vallabhapurapu Sivakumar; Kirsten J L Hammond; Norma Howells; Klaus Pfeffer; Falk Weih
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

View more
  23 in total

Review 1.  Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease.

Authors:  Neil Shah; Jochen Kammermeier; Mamoun Elawad; Erik-Oliver Glocker
Journal:  Curr Allergy Asthma Rep       Date:  2012-10       Impact factor: 4.806

Review 2.  Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling.

Authors:  Adriana Almeida de Jesus; Scott W Canna; Yin Liu; Raphaela Goldbach-Mansky
Journal:  Annu Rev Immunol       Date:  2015-02-20       Impact factor: 28.527

3.  Dendritic cells from humans with hypomorphic mutations in IKBKG/NEMO have impaired mitogen-activated protein kinase activity.

Authors:  Chi A Ma; Hong-Ying Wang; Stephane Temmerman; Yongge Zhao; Liming Wu; Ronald L Hornung; Diane Wara; Ashish Jain
Journal:  Hum Mutat       Date:  2011-03       Impact factor: 4.878

4.  Successful treatment with infliximab for inflammatory colitis in a patient with X-linked anhidrotic ectodermal dysplasia with immunodeficiency.

Authors:  Tomoyuki Mizukami; Megumi Obara; Ryuta Nishikomori; Tomoki Kawai; Yoshihiro Tahara; Naoki Sameshima; Kousuke Marutsuka; Hiroshi Nakase; Nobuhiro Kimura; Toshio Heike; Hiroyuki Nunoi
Journal:  J Clin Immunol       Date:  2011-10-13       Impact factor: 8.317

5.  A novel gain-of-function IKBA mutation underlies ectodermal dysplasia with immunodeficiency and polyendocrinopathy.

Authors:  Lena F Schimke; Nikolaus Rieber; Stacey Rylaarsdam; Otávio Cabral-Marques; Nicholas Hubbard; Anne Puel; Laura Kallmann; Stephanie Anover Sombke; Gundula Notheis; Hans-Peter Schwarz; Birgit Kammer; Tomas Hökfelt; Reinald Repp; Capucine Picard; Jean-Laurent Casanova; Bernd H Belohradsky; Michael H Albert; Hans D Ochs; Ellen D Renner; Troy R Torgerson
Journal:  J Clin Immunol       Date:  2013-05-25       Impact factor: 8.317

6.  Very early onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantation.

Authors:  Dhaarini Murugan; Michael H Albert; Jörg Langemeier; Jens Bohne; Jacek Puchalka; Päivi M Järvinen; Fabian Hauck; Anne K Klenk; Christine Prell; Stephanie Schatz; Jana Diestelhorst; Barbara Sciskala; Naschla Kohistani; Bernd H Belohradsky; Susanna Müller; Thomas Kirchner; Mark R Walter; Philip Bufler; Aleixo M Muise; Scott B Snapper; Sibylle Koletzko; Christoph Klein; Daniel Kotlarz
Journal:  J Clin Immunol       Date:  2014-02-12       Impact factor: 8.317

Review 7.  Primary Immunodeficiencies and Inflammatory Disease: A Growing Genetic Intersection.

Authors:  Nassima Fodil; David Langlais; Philippe Gros
Journal:  Trends Immunol       Date:  2016-01-12       Impact factor: 16.687

8.  Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-κB activation and autoinflammatory disease.

Authors:  Jevgenia Zilberman-Rudenko; Linda Monaco Shawver; Alex W Wessel; Yongquan Luo; Martin Pelletier; Wanxia Li Tsai; Younglang Lee; Spiridon Vonortas; Laurence Cheng; Jonathan D Ashwell; Jordan S Orange; Richard M Siegel; Eric P Hanson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-22       Impact factor: 11.205

9.  T Cell Impairment Is Predictive for a Severe Clinical Course in NEMO Deficiency.

Authors:  Stephanie Heller; Uwe Kölsch; Thomas Magg; Renate Krüger; Andrea Scheuern; Holm Schneider; Anna Eichinger; Volker Wahn; Nadine Unterwalder; Myriam Lorenz; Klaus Schwarz; Christian Meisel; Ansgar Schulz; Fabian Hauck; Horst von Bernuth
Journal:  J Clin Immunol       Date:  2020-01-21       Impact factor: 8.317

Review 10.  Genetics of inflammatory bowel disease from multifactorial to monogenic forms.

Authors:  Anna Monica Bianco; Martina Girardelli; Alberto Tommasini
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.